Screener
ANI Pharmaceuticals ANIP Cortrophin Gel — Net Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Products and Services (in thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Rare Disease and Brands | ||||
| Cortrophin Gel | $117,126 | $81,647 | $192,245 | $134,497 |
| ILUVIEN and YUTIQ (1) | 18,718 | 22,316 | 37,973 | 38,425 |
| Rare Disease total net revenues | $135,844 | $103,963 | $230,218 | $172,922 |
| Brands | 11,813 | 13,195 | 24,141 | 38,318 |
| Brand royalties and other revenues | 17,731 | — | 39,271 | — |
| Rare Disease and Brands total net revenues | $165,388 | $117,158 | $293,630 | $211,240 |
| Generics and Other |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's cortrophin gel — net revenues?
- ANI Pharmaceuticals (ANIP) reported cortrophin gel — net revenues of $117.13M in Q2 2026.
- How has ANI Pharmaceuticals's cortrophin gel — net revenues changed year-over-year?
- ANI Pharmaceuticals's cortrophin gel — net revenues increased by 43.5% year-over-year, from $81.65M to $117.13M.
- What is the long-term trend for ANI Pharmaceuticals's cortrophin gel — net revenues?
- Over 2 years (2022 to 2025), ANI Pharmaceuticals's cortrophin gel — net revenues has grown at a 188.8% compound annual growth rate (CAGR), from $41.69M to $347.78M.
- What does cortrophin gel — net revenues mean?
- This metric represents the total gross sales of a specific pharmaceutical product line or therapeutic brand after accounting for returns, allowances, and rebates. It serves as a primary indicator of market adoption, pricing power, and commercial success for a key revenue-generating asset within the company's portfolio. Monitoring this figure helps investors assess the growth trajectory and competitive positioning of the product in its respective therapeutic category.
Ask your AI about ANI Pharmaceuticals's cortrophin gel — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude